Lantheus
LNTH
Collegium Pharmaceutical
COLL
Constellation Brands
STZ
Halozyme Therapeutics
HALO
AIRPORTS OF THAILAND PUBLIC CO UNSP ADR EACH REP 10 ORD SHS
AIPUY
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 0.35%30.64B | 2.59%8.6B | 4.30%7.2B | -2.57%7.65B | -2.79%7.19B | -1.42%30.53B | 0.55%8.38B | -8.36%6.91B | -5.29%7.85B | 8.58%7.39B |
Operating revenue | 0.35%30.64B | 2.59%8.6B | 4.30%7.2B | -2.57%7.65B | -2.79%7.19B | -1.42%30.53B | 0.55%8.38B | -8.36%6.91B | -5.29%7.85B | 8.58%7.39B |
Cost of revenue | -2.74%20.33B | -1.85%5.35B | 0.38%4.71B | -2.99%5.46B | -6.22%4.82B | -4.54%20.91B | -6.13%5.45B | -11.45%4.69B | -6.99%5.63B | 8.18%5.14B |
Gross profit | 7.06%10.31B | 10.85%3.25B | 12.57%2.5B | -1.53%2.19B | 5.06%2.37B | 6.12%9.63B | 15.90%2.93B | -1.07%2.22B | -0.71%2.23B | 9.48%2.25B |
Operating expense | 4.01%9.27B | 2.07%2.66B | 6.83%2.22B | 12.61%2.2B | -3.61%2.19B | 12.93%8.91B | 23.77%2.61B | 4.26%2.08B | 2.90%1.95B | 20.03%2.27B |
-Depreciation and amortization | 21.49%701M | 11.31%187M | 31.21%185M | 29.10%173M | 19.85%157M | 9.28%577M | 30.23%168M | 6.82%141M | -2.19%134M | 0.77%131M |
Other operating expenses | -2.66%2.42B | -12.28%743M | 7.34%541M | 23.48%589M | -16.95%544M | 203.92%2.48B | 234.87%847M | -2.51%504M | -5.92%477M | 55.95%655M |
Operating profit | 45.24%1.04B | 82.24%585M | 96.48%279M | -101.82%-5M | 980.00%176M | -39.44%714M | -23.57%321M | -43.43%142M | -20.52%275M | -112.20%-20M |
Net non-operating interest income expense | -30.61%-64M | -80.00%-18M | 40.00%-15M | -45.45%-16M | -650.00%-15M | -104.17%-49M | 33.33%-10M | -212.50%-25M | -320.00%-11M | 66.67%-2M |
Other net income (expense) | ||||||||||
Income before tax | 55.00%1.09B | 101.71%589M | 180.58%289M | -92.81%21M | 1,330.77%186M | -50.00%700M | -41.83%292M | -60.84%103M | -31.46%292M | -93.78%13M |
Income tax | 35.68%251M | 45.65%134M | 168.00%67M | -89.23%7M | 1,333.33%43M | -25.40%185M | 26.03%92M | -55.36%25M | -26.97%65M | -90.00%3M |
Net income | 61.94%834M | 127.50%455M | 184.62%222M | -93.83%14M | 1,330.00%143M | -55.26%515M | -53.27%200M | -62.32%78M | -32.64%227M | -94.41%10M |
Net income continuous Operations | 61.94%834M | 127.50%455M | 184.62%222M | -93.83%14M | 1,330.00%143M | -55.26%515M | -53.27%200M | -62.32%78M | -32.64%227M | -94.41%10M |
Minority interest income | 12.50%126M | 224.00%81M | -36.36%21M | -47.62%22M | -84.62%2M | -41.97%112M | -58.33%25M | -35.29%33M | -19.23%42M | -55.17%13M |
Net income attributable to the parent company | 76.12%708M | 114.94%374M | 336.96%201M | -104.32%-8M | 4,800.00%141M | -58.04%402M | -52.72%174M | -70.32%46M | -35.09%185M | -102.01%-3M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 76.12%708M | 114.94%374M | 336.96%201M | -104.32%-8M | 4,800.00%141M | -58.04%402M | -52.72%174M | -70.32%46M | -35.09%185M | -102.01%-3M |
Basic earnings per share | 74.80%6.52 | 112.35%3.44 | 330.23%1.85 | -104.07%-0.07 | 4,433.33%1.3 | -58.37%3.73 | -52.77%1.62 | -70.55%0.43 | -35.58%1.72 | -102.14%-0.03 |
Diluted earnings per share | 74.80%6.52 | 112.35%3.44 | 330.23%1.85 | -104.07%-0.07 | 4,433.33%1.3 | -58.37%3.73 | -52.77%1.62 | -70.55%0.43 | -35.58%1.72 | -102.16%-0.03 |
Dividend per share | -46.15%3.5 | 0 | 0 | -46.15%3.5 | 0 | -38.10%6.5 | 0 | 0 | 0.00%6.5 | 0 |
Currency Unit | NOK | NOK | NOK | NOK | NOK | NOK | NOK | NOK | NOK | NOK |